Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Patients With Chronic Low Back Pain

The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

开始日期2026-03-01

申办/合作机构

Vertanical GmbH

NCT07148206

/ Not yet recruiting临床3期IIT

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

The goal of this pilot study is to test novel, adjunctive pharmacotherapy for patients with opioid use disorder (POUD) who may be at risk for overdose and other poor opioid use disorder (OUD) outcomes even after initiating buprenorphine. The investigator team proposes to test the effectiveness of combined dronabinol (synthetic delta-9-tetrahydrocannabinol [THC]) and Epidiolex (cannabidiol [CBD]) - two FDA-approved cannabinoids - to improve retention in buprenorphine treatment and reduce opioid use among POUD who are early in treatment. POUD who are early in treatment are at a critical juncture-a moment of opportunity and motivation, but also of high risk of return to opioid use and loss to follow up.

开始日期2026-01-01

申办/合作机构

Montefiore Medical Center

[+1]

NCT05432284

/ Not yet recruiting临床1期IIT

Behavioral Pharmacology of THC and Beta-Myrcene

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

开始日期2026-01-01

申办/合作机构

The Johns Hopkins University

[+1]

100 项与屈大麻酚相关的临床结果

登录后查看更多信息

100 项与屈大麻酚相关的转化医学

登录后查看更多信息

100 项与屈大麻酚相关的专利（医药）

登录后查看更多信息

13,595

项与屈大麻酚相关的文献（医药）

2026-01-01·TALANTA

A novel electrochemical method for detecting synthetic cannabinoids in e-cigarette and biological samples using a lab-made electrode

Article

作者: Arantes, Luciano C ; Melo, Larissa M A ; Dos Santos, Wallans T P ; Souza, Karla A O ; Aranha, Lívia M S ; Barroso, Cecília N F ; Marton, Marian ; Costa, Jose L ; Vojs, Marian ; Pereira, Thiago F L

Synthetic Cannabinoid Receptor Agonists (SCRAs) are a class of Novel Psychoactive Substances (NPS) that interact with the same receptors (CB1 and CB2) as delta-9-tetrahydrocannabinol (THC). The identification of SCRAs, such as AB-CHMINACA and MDMB-4en-PINACA, is of significant forensic and toxicological interest due to their widespread consumption in several countries and their potential involvement in overdose cases resulting from their high potency, posing a serious public health and safety concern. Currently, no standardized screening methods exist for the detection of SCRAs in forensic and toxicological contexts. This study introduces a novel electroanalytical method that combines laboratory-fabricated boron-doped diamond screen-printed electrodes (SP/BDDE) with square-wave adsorptive stripping voltammetry (SWAdSV) for the detection of AB-CHMINACA and MDMB-4en-PINACA in e-cigarette samples and real biological matrices. For the first time, the electrochemical behavior of these SCRAs is comprehensively investigated, and all their redox processes (P_c1/P_a2 and P_a3) are utilized for selective and accurate identification. The proposed method exhibited a wide linear range (20-100 μM for AB-CHMINACA and 20-70 μM for MDMB-4en-PINACA) with a low detection limit of 0.282 μM, making it highly suitable for forensic applications involving seized samples and toxicological analyses of biological specimens. The stability of the electrochemical response was assessed, with SP/BDDE showing relative standard deviations (RSD) below 10 % for E_p and I_p. Interference studies confirmed the high selectivity of the method for SCRA detection. AB-CHMINACA and MDMB-4en-PINACA were successfully identified in e-cigarette and biological samples, with recovery rates approaching 100 %, indicating minimal matrix effects in these complex samples. Therefore, the proposed method proves to be a promising, rapid, and selective screening approach for the detection of SCRAs in forensic and toxicological scenarios, as a screening test.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations

Review

作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah

Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.

2025-12-01·Epilepsy & Behavior Reports

The role of cannabis in epilepsy illustrated by two case reports

Article

作者: Nix, Bradley T ; Struck, Aaron F ; Boly, Melanie ; Josiah, Anne F ; Semia, Sanaa ; Brace, Cameron J ; Philibert-Rosas, Santiago ; Gidal, Barry E

Cannabis use is increasingly prevalent among individuals with epilepsy, yet its impact on seizure control remains poorly understood. While cannabidiol (CBD) has demonstrated antiseizure properties and gained FDA approval for specific epileptic syndromes, tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, may alter neuronal excitability and potentially exacerbate seizure activity. We present two illustrative case reports of male patients with focal epilepsy and chronic cannabis use who underwent treatment with antiseizure medications and responsive neurostimulation (RNS). In both cases, cannabis use was temporally associated with breakthrough seizures and poor seizure control. These cases highlight the complex and multifactorial relationship between cannabis use and seizure outcomes, including potential pharmacokinetic interactions with antiseizure medications (ASM) and the possibility that cannabis may blunt the neuromodulation effects of RNS. Given the retrospective data and limited detail on cannabis use, these findings should be interpreted with caution. As cannabis use rises among individuals with epilepsy, further research is needed to clarify its potential effects on seizures and treatment response, including neuromodulation.

544

项与屈大麻酚相关的新闻（医药）

2025-10-06

·GlobeNewswire-Health Care

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

TEL AVIV, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the entry into a framework agreement for mutual termination of merger, dated October 6, 2025, by and between the Company, AutoMax Motors Ltd. ("AutoMax") and SciSparc Merger Sub Ltd. This agreement outlines key steps to resolve prior commitments and establish clear repayment terms for the Company’s outstanding loans to AutoMax. The terms of the framework agreement include: Mutual Termination of Merger Agreement: The parties have mutually agreed to terminate the Agreement and Plan of Merger, dated April 10, 2024, as amended (the "Merger Agreement"), in accordance with Section 9.1(a) thereof. Effective immediately, the Merger Agreement is null and void, with no further force or effect. Repayment of $4.25 Million Loan: AutoMax will repay the full $4.25 million principal plus 9% per annum interest, compounded annually, in a single lump-sum payment on January 1, 2028, under the terms of the loan agreement dated January 14, 2024, as amended. Repayment of $2.0 Million Loan: AutoMax will repay the $2.0 million principal in monthly installments of $60,000 each starting November 20, 2025, plus 8% per annum interest, compounded annually up to each payment date. Additionally, all accrued interest from the loan's effective date (February 24, 2025) through November 20, 2025, totaling $114,523, will be paid at the outset. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses repayment terms and timing thereof of the Company’s loans to AutoMax. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972 3-761-7108

并购

2025-10-01

·药明康德

穿越血脑屏障！RNAi疗法新锐完成千万美元融资；首个！FDA受理重磅ADC监管申请……

穿越血脑屏障！RNAi疗法新锐完成千万美元融资 Aerska今日宣布完成2100万美元种子轮融资，由Age1、Backed VC与Speedinvest联合领投，Blueyard、Lingotto（Exor）、Norrsken VC、Kerna、PsyMed、Saras与Ada Ventures等参投。公司专注于开发可系统性给药的RNAi疗法，用于沉默驱动脑部疾病的致病基因。鉴于血脑屏障阻碍基因药物（genetic medicines）进入中枢神经系统（CNS），Aerska提出以抗体-寡核苷酸偶联药物（AOC）为核心的平台技术，通过“脑穿梭（brain shuttles）”机制实现系统性递送、神经元摄取以及在脑内持久的基因表达下调。在管线策略上，Aerska结合外部合作与内部技术创新，并配套建设数据科学能力，推进以精准医疗为导向的神经病学药物研发，率先布局遗传型阿尔茨海默病与帕金森病管线。公司由Jack O’Meara先生、Stuart Milstein博士与David Hardwicke先生共同创立，并拥有在RNA药物、CNS药物发现与临床开发方面经验深厚的管理团队。首个！FDA受理重磅ADC监管申请今日，阿斯利康（AstraZeneca）与第一三共（Daiichi Sankyo）宣布，其所提交的补充生物制品许可申请（sBLA）已获美国FDA受理。该sBLA寻求批准其联合开发的重磅抗体偶联药物Enhertu（trastuzumab deruxtecan）接续紫杉醇、曲妥珠单抗和帕妥珠单抗（THP），作为新辅助疗法，用于治疗成人HER2阳性II期或III期乳腺癌患者。该申请主要基于DESTINY-Breast11临床3期研究的积极结果，FDA预计于2026年5月18日前公布审评结果。根据新闻稿，这是首个3期临床试验证实Enhertu在早期乳腺癌中具有治疗益处。之前公布的试验结果显示，在高风险、局部晚期HER2阳性早期乳腺癌患者中，于术前新辅助治疗阶段使用Enhertu联合THP，在病理学完全缓解（pCR）方面相较于标准治疗方案（剂量密集的阿霉素和环磷酰胺，后使用THP，即ddAC-THP）实现了具有统计学显著性和临床意义的提升。此外，Enhertu联合疗法亦展现出相较标准治疗方案更优的安全性。尽管在分析时无事件生存期（EFS）这一次要终点尚未成熟，但数据显示Enhertu联合THP在EFS方面相较标准治疗呈现出早期积极趋势。试验将继续随访EFS结果。 Enhertu是阿斯利康和第一三共联合开发的ADC疗法。它采用第一三共专有的DXd ADC技术平台设计，由靶向HER2的人源化单克隆抗体通过四肽可裂解连接子，与拓扑异构酶1抑制剂有效载荷连接组成。疗效持久达一年！潜在“first-in-class”药物临床3期结果亮眼 Vertanical今日宣布，两项评估其在研疗法VER-01在慢性下背痛（CLBP）治疗中安全性与有效性的3期临床研究结果已发表于Nature Medicine和Pain & Therapy期刊。VER-01为一款潜在“first-in-class”、大麻（Cannabis sativa）的标准化全谱系提取物。分析显示，VER-01较安慰剂可显著降低慢性下背痛强度，且疗效在连续12个月治疗期间得以维持。该疗法整体耐受性良好，未观察到依赖或停药反应。在另一项与阿片类药物的3期头对头研究中，VER-01在镇痛效果及胃肠道耐受性方面均优于阿片类药物，且未见依赖或滥用迹象。同时，VER-01还能改善慢性疼痛常伴随的关键症状，包括睡眠障碍与体能受损，从而显著提升患者生活质量。Vertanical已在多个欧洲国家提交VER-01的上市许可申请，并计划于2026年初在美国启动3期研究，以支持后续向FDA递交上市申请。参考资料： [1] Aerska Launches with $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain. Retrieved October 1, 2025 from https://www.globenewswire.com/news-release/2025/10/01/3159351/0/en/Aerska-Launches-with-21-Million-in-Financing-to-Develop-RNAi-Medicines-for-Diseases-of-the-Brain.html [2] VERTANICAL Announces Positive Results From the VER-01 Phase 3 Program for the Treatment of Chronic Low Back Pain (CLBP). Retrieved October 1, 2025 from https://www.prnewswire.com/news-releases/vertanical-announces-positive-results-from-the-ver-01-phase-3-program-for-the-treatment-of-chronic-low-back-pain-clbp-302572242.html [3] ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery. Retrieved October 1, 2025 from https://www.businesswire.com/news/home/20250930135764/en/ENHERTU-Followed-by-THP-Supplemental-Biologics-License-Application-Accepted-in-the-U.S.-for-Patients-with-High-Risk-HER2-Positive-Early-Stage-Breast-Cancer-Prior-to-Surgery 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

抗体药物偶联物临床3期临床结果临床2期

2025-10-01

·PRNewswire

VERTANICAL Announces Positive Results From the VER-01 Phase 3 Program for the Treatment of Chronic Low Back Pain (CLBP)

VER-01 significantly reduced pain intensity in chronic low back pain compared with placebo, with effects sustained during 12 months of treatment. VER-01 was generally well tolerated, with no signs of dependence, or withdrawal. In a second Phase 3 head-to-head study comparing VER-01 with opioids, VER-01 demonstrated superior pain reduction and gastrointestinal tolerability. VERTANICAL submitted for marketing authorization in several European countries for the treatment of chronic low back pain. A Phase 3 study in the U.S. is planned to start in early 2026 to support a submission for FDA approval. MUNICH, Oct. 1, 2025 /PRNewswire/ -- Vertanical today announced publication of results from two Phase 3 clinical studies investigating the safety and efficacy of VER-01, a first-in-class standardized full-spectrum extract from Cannabis sativa DKJ127 L, for the treatment of chronic low back pain (CLBP). The Phase 3 findings point to a potential therapeutic breakthrough for the treatment of CLBP. Published in Nature Medicine and Pain & Therapy, the results demonstrate that VER-01 provides superior pain relief and gastrointestinal tolerability compared to opioids, without evidence of dependence or abuse1. VER-01 also improved key symptoms of chronic pain – including sleep disturbances and impaired physical function – resulting in a significant improvement in patients' quality of life 2. "These findings provide powerful evidence that VER-01 could transform how we care for patients with chronic lower back pain, if approved," says Prof. Charles E. Argoff, Professor of Neurology at Albany Medical College and Past President of the American Academy of Pain Medicine. "The results of the Phase 3 studies bring hope to millions living with chronic pain that, if approved, VER-01 could deliver effective pain relief while addressing key safety challenges of current therapies." CLBP affects more than half a billion people worldwide and is the leading cause of disability and reduced quality of life3,4. Yet current pharmacological treatment options remain largely limited to nonsteroidal anti-inflammatory drugs and opioids, both of which have been associated with significant safety concerns and potentially serious side effects, particularly with long-term use 5,6,7. VER-01 shows superiority over placebo in pivotal Phase 3 study In a placebo-controlled double-blind Phase 3 study enrolling 820 patients with CLBP published in Nature Medicine, VER-01 demonstrated significant pain reduction compared with placebo, meeting the study's primary endpoint. After 12 weeks of treatment, patients receiving VER-01 achieved a pain reduction of -1.9 points on the 0- to 10-point pain numerical rating scale (NRS). In an open-label extension phase, pain intensity further decreased to -2.9 points after six months and was sustained over 12 months continued treatment. Effects of VER-01 were particularly pronounced in participants with neuropathic pain and those with severe pain. Study participants receiving VER-01 also reported significantly greater improvements in sleep quality and physical function compared with placebo. VER-01 was generally well tolerated with no evidence of dependence or withdrawal. While mild to moderate adverse events, generally related to dizziness, headache, fatigue, nausea, dry mouth, and somnolence, were more frequent with VER-01 than placebo, most side effects occurred only during the initial 3-week titration phase of the study and were generally transient. The incidence of serious adverse events was comparable to placebo showing no safety signals. VER-01 shows superiority over opioids in ELEVATE head-to-head comparator study A second phase 3 study ("ELEVATE") directly compared VER-01 with opioids in patients with chronic low back pain (CLBP). Published in Pain & Therapy, the study demonstrated superiority of VER-01 to opioids in both efficacy and gastrointestinal tolerability. The Phase 3 open-label study enrolling 384 patients met its primary endpoint, demonstrating a significantly higher incidence of constipation in the opioid group compared to the VER-01 group. Participants receiving VER-01 were four times less likely to develop constipation than those receiving opioids and three times less likely to use laxatives. VER-01 was more effective in alleviating pain than opioids with patients also experiencing improved sleep throughout the 6 months of treatment. Pain reduction was particularly pronounced in participants with neuropathic pain and those with severe pain. "The two Phase 3 studies show that VER-01 could be a transformative therapy," says Prof. Roger Knaggs, Professor of Pain Management and President of the British Pain Society. "Patients and physicians have long sought novel treatments for chronic pain. If approved, VER-01 could represent the first new class of chronic pain medicine for a very long time." About VER-01 VER-01 is an investigational standardized full-spectrum extract from the Cannabis sativa strain DKJ127 L. Its unique phytochemical composition contains a distinct and complex mixture of cannabinoids, terpenes and other bioactive compounds, such as Cannabigerol, β-caryophyllene and α-bisabolol, that act synergistically and contribute to its overall pharmacological effects ("entourage effect"). VER-01 is manufactured using a proprietary extraction process, preserving the plant's full spectrum of bioactive compounds. Based on the Phase 3 data, VERTANICAL submitted VER-01 for marketing authorization in multiple European countries for the treatment of chronic low back pain. An additional pivotal Phase 3 study in the U.S. is planned to start in early 2026 to support the marketing application for VER-01 in the U.S. About VERTANICAL VERTANICAL is a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies for chronic pain. Guided by the vision of a world free of chronic pain, the company is committed to advancing clinical research and development in chronic pain diseases. With over 20 completed preclinical and clinical studies and a comprehensive development program across multiple chronic pain indications, VERTANICAL is recognized as one of the global innovation leaders in the field of chronic pain. VERTANICAL was founded in 2007 and has its global headquarters in Munich, Germany. The company operates one of the world's most advanced GMP facilities for the development and manufacturing of biopharmaceuticals. It maintains an international network of several hundred research and clinical trial sites across the U.S. and multiple European countries. 1 Meissner W, Argoff C, Sator S, Schoder V, Karst M. VER-01 shows enhanced gastrointestinal tolerability, superior pain relief, and improved sleep quality compared to opioids in treating chronic low back pain: a randomized phase 3 clinical trial. Pain Ther (2025), published online on September 30, 2025, doi:10.1007/s40122-025-00773-z 2 Karst M, Meissner W, Sator S, Keßler J, Schoder V, Häuser W. Full-spectrum extract from Cannabis sativa DKJ127 for chronic back pain: a randomized, placebo-controlled phase 3 study. Nat Med (2025), published online on September 29, 2025, doi: 10.1038/s41591-025-03977-0 3 Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8(6):299. doi:10.21037/atm.2020.02.175 4 GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 May 22;5(6):e316-e329. doi: 10.1016/S2665-9913(23)00098-X. PMID: 37273833; PMCID: PMC10234592. 5 Salvo F, Antoniazzi S, Duong M, et al. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2014;13(5):573-585. doi:10.1517/14740338.2014.907792 6 Wirth T, Lafforgue P, Pham T. NSAID: Current limits to prescription. Joint Bone Spine. 2024 Jul;91(4):105685. doi: 10.1016/j.jbspin.2023.105685. Epub 2023 Dec 29. PMID: 38159794. 7 Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576. doi:10.1097/01.j.pain.0000460357.01998.f1 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果上市批准

100 项与屈大麻酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00306	屈大麻酚	A04AD10	DB00470

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
厌食症	美国	Alkem Laboratories Ltd.	1985-05-31
恶心	美国	Alkem Laboratories Ltd.	1985-05-31
呕吐	美国	Alkem Laboratories Ltd.	1985-05-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化疗引起的恶心和呕吐	申请上市	加拿大	Tetra Bio-Pharma, Inc.	2023-05-01
阻塞性睡眠呼吸暂停综合征	临床3期	美国	RespireRx Pharmaceuticals, Inc.	2023-02-01
腰痛	临床3期	德国	Vertanical GmbH	2021-07-07
食欲减退	临床3期	欧洲	Solvay SA	2007-02-15
Tourette 综合征	临床2期	美国	SciSparc Ltd.	2017-02-01
阿尔茨海默症	临床2期	美国	Unimed Pharmaceutical, Inc.	1996-07-29
抑郁症	临床2期	美国	Unimed Pharmaceutical, Inc.	1996-07-29
帕金森病	临床前	加拿大	Pike Therapeutics, Inc.	2024-11-01
认知障碍	临床前	以色列	Therapix Biosciences Ltd /Non-Pain Assets/	2018-05-13
恶病质	药物发现	南美洲	Avicanna, Inc.	2022-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05610813 (Pubmed \| Pain Ther)	临床3期	腰痛	384	VER-01	醖簾襯築獵憲築繭憲淵(製艱鏇簾齋夢衊壓鹽觸) = 選顧獵鏇襯壓簾襯齋獵積選淵夢淵齋顧餘夢鹽 (鑰襯壓觸顧膚淵願顧夢 ) 更多	积极	2025-09-30
				Opioids	鬱糧壓鹹壓憲鏇觸夢襯(鑰觸艱鏇範積鬱繭膚醖) = 淵構鬱淵廠蓋淵膚衊築鏇窪糧夢願壓廠憲齋廠 (蓋醖觸構觸築廠憲憲選 ) 更多
NCT05477875 (CTgov)	临床2期	近视 \| 远视 \| 术后疼痛	35	Cannabidiol (Cannabidiol)	夢鹽觸鏇構衊醖憲遞顧(選壓糧製蓋顧夢願蓋網) = 蓋願構醖餘鏇構築顧範網簾鹹遞襯襯醖膚繭艱 (醖衊廠網築衊鏇積窪獵, 0.95) 更多	-	2025-08-07
				Tylenol T3 (Tylenol T3)	夢鹽觸鏇構衊醖憲遞顧(選壓糧製蓋顧夢願蓋網) = 積艱鑰觸繭鹽鏇範醖積網簾鹹遞襯襯醖膚繭艱 (醖衊廠網築衊鏇積窪獵, 0.89) 更多
NCT05820685 (DOPE, CTgov)	临床4期	疼痛	484	Standard of Care (Standard of Care)	鹹繭廠膚願鑰齋齋夢鏇(醖艱構構艱構蓋蓋憲遞) = 醖繭簾鏇積鑰艱簾壓簾鹽夢範願選壓齋廠餘範 (願觸艱網醖鬱簾壓窪鑰, 鬱積廠鑰範憲範艱糧獵 ~ 觸遞膚範鑰獵齋餘繭醖) 更多	-	2025-06-11
				Standard of Care+Dronabinol (Standard of Care + Dronabinol)	鹹繭廠膚願鑰齋齋夢鏇(醖艱構構艱構蓋蓋憲遞) = 糧鹹壓淵簾構範窪觸壓鹽夢範願選壓齋廠餘範 (願觸艱網醖鬱簾壓窪鑰, 簾糧鹹網齋糧壓糧鹹鹽 ~ 願願襯淵膚願鹹鹽糧窪) 更多
NCT02792257 (THC-AD, CTgov)	临床2期	阿尔茨海默症 \| 躁动	84	Dronabinol (Dronabinol)	憲襯淵網鬱顧襯鹹鹽蓋(鏇廠糧淵膚壓繭鏇遞糧) = 蓋餘鬱醖廠襯觸淵淵顧範蓋鹽衊選憲願憲製鏇 (夢範齋鏇顧憲觸選願鬱, 4.12) 更多	-	2025-05-09
				Placebo (Placebo)	憲襯淵網鬱顧襯鹹鹽蓋(鏇廠糧淵膚壓繭鏇遞糧) = 餘膚鹽遞鑰願鏇鏇襯鬱範蓋鹽衊選憲願憲製鏇 (夢範齋鏇顧憲觸選願鬱, 4.18) 更多
NCT02817698 (CTgov)	早期临床1期	吸烟 \| 大麻滥用 \| 未指明的药物依赖	25	cannabis	蓋窪憲鑰壓範製憲積夢(鹹選簾簾選壓艱廠網鑰) = 鑰壓繭膚遞鏇壓築積窪鏇齋鏇製襯憲鬱蓋範糧 (齋願齋積廠膚淵襯齋獵, 蓋積觸憲繭餘鏇淵鑰願 ~ 齋夢積蓋鏇憲衊顧鏇鏇) 更多	-	2024-12-12
NTIASD1 (Company_Website) 人工标引	临床1/2期	自闭症谱系障碍	14	NTI164	膚廠衊膚獵築鏇觸網築(鹽遞範繭繭糧廠鏇鹽夢) = 遞齋膚網遞遞鬱艱範繭範鹹糧繭築艱鑰艱蓋艱 (顧膚積壓鹹網網壓醖艱 )	积极	2024-12-01
NCT03804840 (AIS, CTgov)	早期临床1期	1型血小板减少症	72	Placebo (Placebo)	範顧廠齋繭夢憲獵遞鬱(願構顧餘範繭壓鏇壓觸) = 窪製醖衊鏇淵製簾選顧鹽簾齋襯衊繭壓願鏇製 (醖顧衊積窪製艱糧壓鹽, .07) 更多	-	2024-09-19
				Dronabinol (7.5 mg THC)	範顧廠齋繭夢憲獵遞鬱(願構顧餘範繭壓鏇壓觸) = 鬱鏇築積繭遞獵構網觸鹽簾齋襯衊繭壓願鏇製 (醖顧衊積窪製艱糧壓鹽, .09) 更多
NCT03809546 (IDT, CTgov)	早期临床1期	1型血小板减少症	60	dextrose (Placebo)	淵壓願築積鹽夢糧獵淵(醖齋鹽壓觸廠築壓繭醖) = 鏇廠鏇構膚艱鑰鹽廠窪構窪艱選簾衊顧餘顧積 (壓蓋繭鹹製構鬱積窪範, 0.047) 更多	-	2024-07-03
				Dronabinol (7.5 mg THC)	淵壓願築積鹽夢糧獵淵(醖齋鹽壓觸廠築壓繭醖) = 觸觸顧窪遞鹽觸鹽憲鬱構窪艱選簾衊顧餘顧積 (壓蓋繭鹹製構鬱積窪範, 0.07) 更多
ACTRN12619000037101 (ASCO2024)	临床2期	晚期癌症	144	10mg/ml THC:10mg/ml CBD combination oil	窪蓋齋蓋餘窪蓋簾蓋艱(憲構憲衊鑰憲蓋齋鑰鏇) = 26/69 and 12/72 壓構顧築艱網鹽繭網蓋 (壓繭鬱淵範膚選膚蓋遞 ) 更多	不佳	2024-05-24
				Placebo
NCT05192239 (CTgov)	早期临床1期	-	17	Placebo (Placebo)	獵壓簾淵窪遞獵糧醖製(繭鹽衊窪網鏇築鏇夢鹽) = 醖鏇鏇積艱鹽願襯遞餘齋窪網鏇醖鹹醖餘製製 (網積鹽壓鬱繭餘夢壓遞, 0.3711208) 更多	-	2024-04-22
				THC 5 (10 mg THC)	獵壓簾淵窪遞獵糧醖製(繭鹽衊窪網鏇築鏇夢鹽) = 蓋鹹獵蓋願獵窪積願襯齋窪網鏇醖鹹醖餘製製 (網積鹽壓鬱繭餘夢壓遞, 0.358376) 更多